Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Defne, Yarar"'
Autor:
Katarina Blagovic, Carolyne K. Smith, Amritha Ramakrishnan, Lindsay Moore, David R. Soto, Zachary Thompson, Adam P. Stockmann, Sonia Kruszelnicki, Akshi Thakkar, Jason Murray, Sebastian Torres, Bersabel Wondimagegnhu, Roslyn Yi, Maisam Dadgar, Abdul M. Paracha, Claire Page, Louise Clear, Omer A. Chaudhry, Melissa Myint, Devin T. Bridgen, Jonathan B. Gilbert, Katherine J. Seidl, Armon Sharei, Scott Loughhead, Howard Bernstein, Defne Yarar
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Activation of T cell responses is essential for effective tumor clearance; however, inducing targeted, potent antigen presentation to stimulate T cell responses remains challenging. We generated Activating Antigen Carriers (AACs) by engineering red b
Externí odkaz:
https://doaj.org/article/ab428f4295ae4b128ffb05a77f629f09
Autor:
Katarina Blagovic, Amritha Ramakrishnan, Armon Sharei, Howard Bernstein, Katherine Seidl, Defne Yarar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/663d05a7bace45eba93512c95ad89c1d
Autor:
Katarina Blagovic, Armon Sharei, Howard Bernstein, Katherine Seidl, Defne Yarar, Scott Loughhead, Emrah Ozay, Matthew Booty, David Soto, Olivia Pryor, Adam Stockmann, Disha Subramanya, Kelly Volk
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/cb105885adca49f0b52ad13cefdddb92
Figure legends describing supplemental data.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60c72ad73e358543585ebb7ccd20821d
https://doi.org/10.1158/1535-7163.22502530.v1
https://doi.org/10.1158/1535-7163.22502530.v1
Growth rates of engineered OVCAR8 cells grown as spheroids.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::160144379c4fc5b5227888914dba81f9
https://doi.org/10.1158/1535-7163.22502533
https://doi.org/10.1158/1535-7163.22502533
Western blots and quantification of time course of HRG-stimulated signaling (pAKT-S473, pERK1/2) in NCI-N87, SKBR3, OVCAR8, and HCC1937 control cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f84b9ccc8cb4c254b9d2d44a5e8d8be
https://doi.org/10.1158/1535-7163.22502536.v1
https://doi.org/10.1158/1535-7163.22502536.v1
Table showing indication, specific PIK3CA and PTEN mutations, as well as ErbB2 amplification status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10d2f4a0f6ef470669ac1b581073e91d
https://doi.org/10.1158/1535-7163.22502527.v1
https://doi.org/10.1158/1535-7163.22502527.v1
Table showing raw values of tumor sizes of OVCAR8 EV-neg, H1047R-neg, and H1047R-ErbB3 expressing xenografts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4de1f6bfaa2d0c5f0fa6cf184b208518
https://doi.org/10.1158/1535-7163.22502521
https://doi.org/10.1158/1535-7163.22502521
Growth rates of control (GFP/EV) or PIK3CA- (WT or H1047R mutant) expressing NCI-N87, SKBR3, OVCAR8, and HCC1937 cells grown in 3D culture.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::283c77337097737b2df04e10d8fa73ba
https://doi.org/10.1158/1535-7163.22502539.v1
https://doi.org/10.1158/1535-7163.22502539.v1
Autor:
Matthew G. Booty, Kelan A. Hlavaty, Adam Stockmann, Emrah Ilker Ozay, Carolyne Smith, Lina Tian, Edylle How, Disha Subramanya, Anita Venkitaraman, Christian Yee, Olivia Pryor, Kelly Volk, Katarina Blagovic, Ildefonso Vicente-Suarez, Defne Yarar, Melissa Myint, Amy Merino, Jonathan Chow, Tarek Abdeljawad, Harry An, Sophia Liu, Shirley Mao, Megan Heimann, LeeAnn Talarico, Miye K. Jacques, Eritza Chong, Lucas Pomerance, John T. Gonzalez, Ulrich H. von Andrian, Klavs F. Jensen, Robert Langer, Hendrik Knoetgen, Christine Trumpfheller, Pablo Umaña, Howard Bernstein, Armon Sharei, Scott M. Loughhead
Publikováno v:
The Journal of Immunology. 208:929-940
CD8+ T cell responses are the foundation of the recent clinical success of immunotherapy in oncologic indications. Although checkpoint inhibitors have enhanced the activity of existing CD8+ T cell responses, therapeutic approaches to generate Ag-spec